etrasimod vs ozanimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

etrasimod · Velsipity

Marketed by Pfizer and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,4,5 modulator)
Reliable signal

NCT03945188 · Phase 3 · completed

Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.

Next expected readout: June 2027 · NCT07782242 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)

Result source: NCT03945188

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,5 modulator)
Reliable signal

NCT02435992 · Phase 3 · completed

Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.

Next expected readout: July 2032 · NCT05076175 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)

Result source: NCT02435992

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointetrasimodozanimod
Clinical remission (induction)27% vs 7.4%+19.6 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 24.8% vs 15.2% 2 mg · wk 12 · n 222 · Phase 3 · primary NCT03996369
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · primary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · primary NCT05061446
  • 33% vs 8.1% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 16% vs 8.1% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 28.3% vs 11.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516
Clinical remission (maintenance)32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
3 other results
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · primary NCT04706793
  • 49.1% vs 17.4% 2 mg · wk 52 · n 171 · Phase 3 · secondary NCT03945188
  • 26% vs 18.3% wk 52 · n 127 · Phase 2 · primary NCT04607837
37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516
Clinical response (induction)62.4% vs 34.1%+28.3 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 62.2% vs 41.1% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 50.6% vs 32.5% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 43.7% vs 32.5% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 55.9% vs 36.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 52.6% vs 7.1% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 33.3% vs 7.1% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
Endoscopic improvement (induction)35% vs 14.1%+20.9 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 30.6% vs 18.8% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 41.8% vs 17.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 22.5% vs 17.8% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 44.1% vs 20% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
Corticosteroid-free remission (maintenance)32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
6 other results
  • 31% vs 7.5% 2 mg · wk 52 · n 87 · Phase 3 · secondary NCT03945188
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · secondary NCT04706793
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 16.2% vs 16.7% wk 52 · n 37 · Phase 2 · secondary NCT04607837
  • 30% vs 30% wk 52 · n 20 · Phase 2 · secondary NCT04607837
31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992

Clinical remission (induction)

etrasimod
27% vs 7.4%+19.6 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 24.8% vs 15.2% 2 mg · wk 12 · n 222 · Phase 3 · primary NCT03996369
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · primary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · primary NCT05061446
  • 33% vs 8.1% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 16% vs 8.1% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 28.3% vs 11.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
ozanimod
18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516

Clinical remission (maintenance)

etrasimod
32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
3 other results
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · primary NCT04706793
  • 49.1% vs 17.4% 2 mg · wk 52 · n 171 · Phase 3 · secondary NCT03945188
  • 26% vs 18.3% wk 52 · n 127 · Phase 2 · primary NCT04607837
ozanimod
37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516

Clinical response (induction)

etrasimod
62.4% vs 34.1%+28.3 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 62.2% vs 41.1% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 50.6% vs 32.5% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 43.7% vs 32.5% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 55.9% vs 36.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 52.6% vs 7.1% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 33.3% vs 7.1% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
ozanimod
47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516

Endoscopic improvement (induction)

etrasimod
35% vs 14.1%+20.9 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 30.6% vs 18.8% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 41.8% vs 17.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 22.5% vs 17.8% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 44.1% vs 20% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
ozanimod
27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516

Corticosteroid-free remission (maintenance)

etrasimod
32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
6 other results
  • 31% vs 7.5% 2 mg · wk 52 · n 87 · Phase 3 · secondary NCT03945188
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · secondary NCT04706793
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 16.2% vs 16.7% wk 52 · n 37 · Phase 2 · secondary NCT04607837
  • 30% vs 30% wk 52 · n 20 · Phase 2 · secondary NCT04607837
ozanimod
31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. etrasimod: 11 of 11 rows · ozanimod: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricetrasimod
Rows use multiple source trials
ozanimod
Rows use multiple source trials
Clinical Remission
responder rate · % of participants
Extension (open-label)
39.3% (n=84) vs 25% (n=4) placebo @ 46wk2 mga,b,c
NCT02536404 · Phase 2 · registry result, not featured evidence
44% (n=266) vs 41.6% (n=113) placebo @ 46wka,b,c
NCT02531126 · Phase 3 · monotherapy
Clinical Response
responder rate · % of participants
Maintenance
48.2% (n=274) vs 23% (n=135) placebo @ 52wk2 mgb
NCT03945188 · Phase 3 · monotherapy
1 other source trial
44.1% (n=127) vs 38.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
60% (n=230) vs 39.1% (n=69) placebo @ 52wkb
NCT02435992 · Phase 3 · monotherapy
Clinical Response
responder rate · % of participants
Extension (open-label)
78.6% (n=84) vs 75% (n=4) placebo @ 46wk2 mga,b,c
NCT02536404 · Phase 2 · registry result, not featured evidence
77% (n=261) vs 81.8% (n=110) placebo @ 46wka,b,c
NCT02531126 · Phase 3 · monotherapy
Endoscopic Improvement
responder rate · % of participants
Maintenance
37.2% (n=274) vs 10.4% (n=135) placebo @ 52wk2 mgb
NCT03945188 · Phase 3 · monotherapy
1 other source trial
32.3% (n=127) vs 23.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
45.7% (n=230) vs 29% (n=69) placebo @ 52wkb
NCT02435992 · Phase 3 · monotherapy
Mucosal Healing
responder rate · % of participants
Induction
21.2% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mgb,d
NCT03945188 · Phase 3 · monotherapy
3 other source trials
16.2% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
5.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
12.6% (n=429) vs 3.7% (n=216) placebo @ 10wke,b,d
NCT02435992 · Phase 3 · monotherapy
show 1 more dose
11.4% (n=367) vs 3.7% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
Mucosal Healing
responder rate · % of participants
Maintenance
26.6% (n=274) vs 8.1% (n=135) placebo @ 52wk2 mgb
NCT03945188 · Phase 3 · monotherapy
29.6% (n=230) vs 10.1% (n=69) placebo @ 52wkb
NCT02435992 · Phase 3 · monotherapy
Total Mayo
absolute change · score
Induction
-3.35 vs -2.08 placebo score @ 12wk2 mge,b,c,f
NCT02447302 · Phase 2 · registry result, not featured evidence
show 1 more dose
-2.69 vs -2.08 placebo score @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
-3.4 vs -2 placebo score @ 8wk1 mge,b,c,f
NCT01647516 · Phase 2 · registry result, not featured evidence
show 1 more dose
-2.6 vs -2 placebo score @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
Dropout rate
44.3%2 mgg
NCT03945188 · Phase 3 · monotherapy
show 8 more results
10.5%2 mg
NCT03996369 · Phase 3 · monotherapy
35.7%2 mg
NCT04706793 · Phase 3 · monotherapy
37.4%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
5.9%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
17.9%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
8%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
9.6%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
—1mgg
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
11.7%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
46.3%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
69.5%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
4.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.5%2 mgg
NCT03945188 · Phase 3 · monotherapy
show 8 more results
3.8%2 mg
NCT03996369 · Phase 3 · monotherapy
—2 mg
NCT04706793 · Phase 3 · monotherapy
5.2%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
4.5%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
6%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
7.7%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
—1mgg
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
3.3%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
7.4%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
6.1%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
3%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Serious AEs
6.9%2 mgg
NCT03945188 · Phase 3 · monotherapy
show 8 more results
2.5%2 mg
NCT03996369 · Phase 3 · monotherapy
3.6%2 mg
NCT04706793 · Phase 3 · monotherapy
6.5%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
6.3%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
5.8%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
4%1mgg
NCT02435992 · Phase 3 · monotherapy
show 15 more results
6.3%1mg
NCT02435992 · Phase 3 · monotherapy
5.2%1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
—RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
14.8%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
17.2%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
3%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
2.4%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
18.6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
1.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
25%0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
9.1%Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
2 mgg
anaemia 8.3% (placebo 9.7%)
headache 8.3% (placebo 4.9%)
covid-19 6.6% (placebo 5.6%)
NCT03945188 · Phase 3 · monotherapy
show 8 more results
2 mg
anaemia 5.9% (placebo 6.9%)
headache 4.6% (placebo 1.7%)
nausea 4.2% (placebo 1.7%)
NCT03996369 · Phase 3 · monotherapy
2 mg
headache 14.3% (placebo 14.3%)
malaise 10.7% (placebo 0%)
pyrexia 10.7% (placebo 14.3%)
NCT04706793 · Phase 3 · monotherapy
colitis ulcerative 12.3% (placebo 10.1%)
covid-19 9.7% (placebo 8.9%)
alanine aminotransferase increased 8.4% (placebo 1.3%)
NCT04607837 · Phase 2 · registry result, not featured evidence
2 mg
alanine aminotransferase increased 5.3% (placebo 0%)
back pain 5.3% (placebo 0%)
blood creatine phosphokinase increased 5.3% (placebo 0%)
NCT05061446 · Phase 2 · registry result, not featured evidence
1 mg
stomatitis 11.8% (placebo 0%)
anaemia 5.9% (placebo 0%)
cataract 5.9% (placebo 0%)
NCT05061446 · Phase 2 · registry result, not featured evidence
2 mg
colitis ulcerative 14.3% (placebo 16.7%)
anaemia 8.9% (placebo 0%)
gamma-glutamyltransferase increased 8.9% (placebo 0%)
NCT02536404 · Phase 2 · registry result, not featured evidence
2 mg
anaemia 6% (placebo 3.7%)
headache 6% (placebo 1.9%)
colitis ulcerative 4% (placebo 1.9%)
NCT02447302 · Phase 2 · registry result, not featured evidence
1 mg
upper respiratory tract infection 7.7% (placebo 3.7%)
colitis ulcerative 5.8% (placebo 1.9%)
anaemia 3.8% (placebo 3.7%)
NCT02447302 · Phase 2 · registry result, not featured evidence
1mgg
anaemia 3.5% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
show 11 more results
1mg
anaemia 4.1% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
1mg
anaemia 0.9% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
covid-19 25.9% (placebo 16.8%)
lymphopenia 16.7% (placebo 17.3%)
leukopenia 7.4% (placebo 4.1%)
NCT02531126 · Phase 3 · monotherapy
lymphopenia 16.3% (placebo 17.3%)
covid-19 11.3% (placebo 16.8%)
lymphocyte count decreased 10.8% (placebo 12.8%)
NCT02531126 · Phase 3 · monotherapy
1 mg
alanine aminotransferase increased 3% (placebo 0%)
headache 3% (placebo 4.6%)
anaemia 1.5% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
alanine aminotransferase increased 2.4% (placebo 0%)
colitis ulcerative 2.4% (placebo 1.5%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
hypertension 11.9% (placebo 0%)
gamma-glutamyltransferase increased 8.5% (placebo 0%)
upper respiratory tract infection 8.5% (placebo 3.1%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
anaemia 6.2% (placebo 6.2%)
colitis ulcerative 3.1% (placebo 1.5%)
back pain 1.5% (placebo 1.5%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
alanine aminotransferase increased 2.8% (placebo 0%)
nasopharyngitis 2.8% (placebo 0%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg/1 mg
anaemia 5.4% (placebo 6.2%)
gamma-glutamyltransferase increased 5.4% (placebo 0%)
lymphocyte count decreased 5.4% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence
anaemia 7.3% (placebo 6.2%)
colitis ulcerative 7.3% (placebo 1.5%)
bronchitis 5.5% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 12 weeks versus 10 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 12 weeks versus 8 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

etrasimod

Symptomatic Remission 46% (n=274) vs 21.5% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 19 more results
43.4% (n=274) vs 18.5% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
15.3% (n=274) vs 8.9% (n=135) placebo @ 2wk2 mg
NCT03945188 · Phase 3 · monotherapy
28.1% (n=274) vs 13.3% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
37.6% (n=274) vs 20.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
43.1% (n=274) vs 21.5% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
43.8% (n=274) vs 20% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
44.9% (n=274) vs 23.7% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
44.5% (n=274) vs 18.5% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
42% (n=274) vs 18.5% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
42% (n=274) vs 15.6% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
46.8% (n=222) vs 29.5% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
16.2% (n=222) vs 10.7% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
27.5% (n=222) vs 16.1% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
38.7% (n=222) vs 24.1% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
39.3% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
31.6% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
20% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
37% (n=127) vs 30% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
36.2% (n=127) vs 25% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical Remission 17.9% (n=274) vs 2.2% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 2 more results
7.1% (n=28) vs 0% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
16.5% (n=127) vs 5% (n=60) placebo
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical 44.9% (n=274) vs 18.5% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Sustained Mucosal Healing 13.5% (n=274) vs 2.2% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Endoscopic Normalization 14.6% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 4 more results
26.3% (n=274) vs 5.9% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
17.1% (n=222) vs 8% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
0% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
Sustained Endoscopic Normalization 10.6% (n=274) vs 1.5% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Complete Symptomatic Remission 5.8% (n=274) vs 2.2% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 16 more results
11.3% (n=274) vs 4.4% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
16.8% (n=274) vs 6.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
23% (n=274) vs 6.7% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
21.2% (n=274) vs 5.9% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
22.3% (n=274) vs 4.4% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
22.3% (n=274) vs 8.1% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
23% (n=274) vs 3% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
21.2% (n=274) vs 5.9% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
19.7% (n=274) vs 2.2% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
24.5% (n=274) vs 4.4% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
4.5% (n=222) vs 1.8% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
11.7% (n=222) vs 3.6% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
14% (n=222) vs 7.1% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
18% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
20.5% (n=127) vs 20% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
20.5% (n=127) vs 20% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Non-invasive Clinical 38.3% (n=274) vs 33.3% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 10 more results
56.2% (n=274) vs 39.3% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
63.1% (n=274) vs 43% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
65.7% (n=274) vs 42.2% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
55.5% (n=274) vs 30.4% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
57.3% (n=274) vs 28.1% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
56.6% (n=274) vs 30.4% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
54% (n=274) vs 25.2% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.5% (n=274) vs 23% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.1% (n=274) vs 21.5% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
50.4% (n=274) vs 23.7% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
Symptomatic 39.4% (n=274) vs 33.3% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 14 more results
57.3% (n=274) vs 40% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
64.6% (n=274) vs 43.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
66.4% (n=274) vs 42.2% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
55.5% (n=274) vs 31.1% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
57.7% (n=274) vs 28.1% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
56.9% (n=274) vs 30.4% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
54.7% (n=274) vs 25.2% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.8% (n=274) vs 23% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.5% (n=274) vs 21.5% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
50.7% (n=274) vs 23.7% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
39.6% (n=222) vs 24.1% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
56.3% (n=222) vs 41.1% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
68.5% (n=222) vs 46.4% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
68.5% (n=222) vs 50% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
Non-invasive Clinical 39.2% (n=222) vs 24.1% (n=112) placebo @ 2wk2 mg
responder rate · % of participants
NCT03996369 · Phase 3 · monotherapy
show 3 more results
55.9% (n=222) vs 41.1% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
68% (n=222) vs 45.5% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
67.6% (n=222) vs 50% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
Histologic-Endoscopic Mucosal Improvement 25.2% (n=127) vs 15% (n=60) placebo @ 52wk
responder rate · % of participants
NCT04607837 · Phase 2 · registry result, not featured evidence
show 1 more result
29.1% (n=127) vs 13.3% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical 39.3% (n=84) vs 50% (n=4) placebo @ 46wk2 mg
responder rate · % of participants
Extension (open-label)
NCT02536404 · Phase 2 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

ozanimod

Durable Clinical Remission 17.8% (n=230) vs 7.2% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Endoscopic Improvement 49.7% (n=290) vs 51.2% (n=121) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
41.4% (n=30) vs 51.2% (n=121) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
58.6% (n=290) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50% (n=30) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
60.8% (n=290) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
57.7% (n=30) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=290) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.3% (n=30) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
60.9% (n=290) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 38% (n=266) vs 40.7% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
41.6% (n=266) vs 52.2% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
45.1% (n=266) vs 55.1% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.3% (n=266) vs 37% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
48.2% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Histologic Remission 25.4% (n=276) vs 19.4% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
48.1% (n=30) vs 19.4% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
32.8% (n=276) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
26.7% (n=30) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
32.4% (n=276) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
48% (n=30) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.5% (n=276) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=30) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.1% (n=276) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Mucosal Healing 20.4% (n=276) vs 14.8% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
25.9% (n=30) vs 14.8% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
28% (n=276) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
20% (n=30) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
27.4% (n=276) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
44% (n=30) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
43.9% (n=276) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
37.5% (n=30) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
46.3% (n=276) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Complete Mayo -1.8 vs -3.5 placebo score @ 46wk
absolute change · score
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 6 more results
-2.2 vs -3.7 placebo score @ 94wk
NCT02531126 · Phase 3 · monotherapy
-2.5 vs -4.2 placebo score @ 142wk
NCT02531126 · Phase 3 · monotherapy
-2.6 vs -3.6 placebo score @ 190wk
NCT02531126 · Phase 3 · monotherapy
-2.9 vs -3.4 placebo score @ 238wk
NCT02531126 · Phase 3 · monotherapy
-3.9 vs -4.1 placebo score @ 286wk
NCT02531126 · Phase 3 · monotherapy
-4.4 vs -4.5 placebo score @ 334wk
NCT02531126 · Phase 3 · monotherapy
Complete Mayo -4 score @ 382wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT02531126 · Phase 3 · monotherapy
Partial Mayo -1.4 vs -2.8 placebo score @ 46wk
absolute change · score
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 7 more results
-1.8 vs -2.9 placebo score @ 94wk
NCT02531126 · Phase 3 · monotherapy
-1.9 vs -3.1 placebo score @ 142wk
NCT02531126 · Phase 3 · monotherapy
-2 vs -3 placebo score @ 190wk
NCT02531126 · Phase 3 · monotherapy
-2.2 vs -2.8 placebo score @ 238wk
NCT02531126 · Phase 3 · monotherapy
-3.5 vs -3.5 placebo score @ 286wk
NCT02531126 · Phase 3 · monotherapy
-2.8 vs -2.5 placebo score @ 334wk
NCT02531126 · Phase 3 · monotherapy
-4 vs -6 placebo score @ 382wk
NCT02531126 · Phase 3 · monotherapy
Mayo 9 -1.3 vs -2.4 placebo score @ 46wk
absolute change · score
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 6 more results
-1.5 vs -2.5 placebo score @ 94wk
NCT02531126 · Phase 3 · monotherapy
-1.6 vs -2.8 placebo score @ 142wk
NCT02531126 · Phase 3 · monotherapy
-1.7 vs -2.4 placebo score @ 190wk
NCT02531126 · Phase 3 · monotherapy
-2 vs -2.2 placebo score @ 238wk
NCT02531126 · Phase 3 · monotherapy
-2.8 vs -3 placebo score @ 286wk
NCT02531126 · Phase 3 · monotherapy
-3.1 vs -3.5 placebo score @ 334wk
NCT02531126 · Phase 3 · monotherapy
Mayo 9 -3 score @ 382wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT02531126 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · ozanimod's landscape